Navigation Links
AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule
Date:6/15/2009

differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments except if we are requested by a governmental authority or applicable law.


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia
2. AEterna Zentaris Discloses Preliminary Phase 2 Trial Results for Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer
3. AEterna Zentaris Acquires All Assets from Ardana for Growth Hormone Secretagogue Compound, AEZS-130
4. AEterna Zentaris Presents Data Supporting Evaluation of AEZS-108 in Prostate Cancer at ASCO Meeting
5. AEterna Zentaris to Present Data Supporting Evaluation of AEZS-108 in Prostate Cancer at Upcoming ASCO Meeting
6. AEterna Zentaris to Announce First Quarter 2009 Financial and Operating Results and Hold Annual Shareholder Meeting on May 6, 2009
7. AEterna Zentaris Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement
8. AEterna Zentaris Presents Phase 1 Results for AEZS-112 in Patients with Advanced Cancer and Lymphoma at AACR Annual Meeting in Denver
9. AEterna Zentaris Presents Two Posters on its PI3K Inhibitor Compound, AEZS-126, at AACR Annual Meeting
10. AEterna Zentaris To Present Data on Anticancer Compounds AEZS-112 and AEZS-126 at AACR Annual Meeting
11. AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... DALLAS , June 29, 2015 ... Type (DNA, RNA, XNA), by Application (Diagnostics, Therapeutics, R&D), by ... Biotechnology & Pharmaceutical Companies, CRO) - Global Forecast to 2020", ... reach $244.93 Million by 2020 from $107.56 Million in 2015, ... market T ables and 67 F ...
(Date:6/29/2015)... Elsevier , a world-leading provider of ... announced the highlights of its journal Impact Factor performance ... (JCR) published by Thomson Reuters, Elsevier saw 55% of ... ahead of the aggregate across other journals. In 2014, ... categories, up from 61 in 2013. An ...
(Date:6/26/2015)... ... June 26, 2015 , ... Charm Sciences, Inc. is pleased ... Stockyards Administration (GIPSA) awarded a five year contract to Charm Sciences to monitor ... ROSA DONQ-FAST5 Test. This 5 minute quantitative test extracts DON from samples using ...
(Date:6/26/2015)... 23, 2015 Research ... of the "Global Cancer Biosimilars Market Opportunity ... Market introduction of cancer biosimilar is required because ... Chemotherapeutic drugs have dominated the cancer segment for ... introduced in past few years. They are biologic ...
Breaking Biology Technology:Aptamers Market Worth $244.93 Million by 2020 2Aptamers Market Worth $244.93 Million by 2020 3Aptamers Market Worth $244.93 Million by 2020 4Elsevier Announces 2014 Citation Impact Highlights 2Elsevier Announces 2014 Citation Impact Highlights 3USDA-GIPSA (FGIS) Awards 5 Year Contract for Vomitoxin Tests to Charm Sciences 2Global Cancer Biosimilars Market Opportunity Outlook 2Global Cancer Biosimilars Market Opportunity Outlook 3
... have a number of juicy topics I wanted to review ... biotech/medical device conference (BIOMED 2006), recent participation in meetings about ... happenings in Japan, and other research that has crossed my ... on why I originally wanted to start writing this column. ...
... The remarkable rate of development in the information technology ... experts in the field. Staying astride the flow of ... professionals and students alike. , ,That is why IT ... and mutual assistance, especially when the goal is educating ...
... invented by University of Wisconsin-Madison engineers promise ... amazing array of materials. , ,Historically, the semiconductor ... to grow and etch the thin films of material ... devices. But as thin as those chips might seem, ...
Cached Biology Technology:The world of in-vitro diagnostics is another Midwest success story 2The world of in-vitro diagnostics is another Midwest success story 3The world of in-vitro diagnostics is another Midwest success story 4The world of in-vitro diagnostics is another Midwest success story 5The world of in-vitro diagnostics is another Midwest success story 6MATC boot camp keeps IT instructors up to date 2MATC boot camp keeps IT instructors up to date 3MATC boot camp keeps IT instructors up to date 4MATC boot camp keeps IT instructors up to date 5UW produces fast and flexible computer chip 2
(Date:6/24/2015)... YORK , June 24, 2015 The ... rate. The major drivers for the market include growth ... number of new drug launches. Over the years, the ... increased. Between 2001 and 2010, the FDA approved 225 ... according to WIPO, Europe accounted ...
(Date:6/24/2015)... , June 24, 2015  Synaptics Inc. ... human interface solutions, today announced that Sharp has ... provide secure authentication for its latest flagship smartphone ... more than 200 million shipments of its fingerprint ... reinforces Synaptics, strength, scalability and leadership in the ...
(Date:6/24/2015)... , June 24, 2015 Biometry ... with emerging biometric password solution one face in. ... one face in, entering the ... ground-breaking and affordable multifactor-authentication biometric answer to the ... technology, provided in partnership with KeyLemon, one face ...
Breaking Biology News(10 mins):Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
... a high-fat diet during pregnancy increases the chance of stillbirth, ... The new data show eating a typical American diet, which ... to the placenta, the temporary organ that nourishes the unborn ... contributes to stillbirth was unclear. The findings are published in ...
... PHILADELPHIA (June 2, 2011) -- Although bitterness can sometimes be ... chocolate more often bitter taste causes rejection that can ... especially true for children. Now, scientists from the Monell Center ... inhibits bitterness by acting directly on a subset of bitter ...
... agricultural sustainability in developing countries, but only with the ... networks they depend on, say Stanford University researchers. Their ... of the Proceedings of the National Academy of ... that technology information flows to farmers through a direct ...
Cached Biology News:Study reveals how high-fat diet during pregnancy increases risk of stillbirth 2New bitter blocker discovered 2Farmer networks hold key to agricultural innovation in developing countries, Stanford study finds 2
... Amplification Kit, 100 reactions. Prepare circular ... 4-6 h.Generate microgram quantities of template ... material.Use amplified DNA directly for cycle ... or M13 liquid cultures, colonies, plaques, ...
Polypropylene test tube racks, used in Thermo Forma's line of Test Tube Rack holders...
For quantitative determination of Aldolase in Serum (an indicator of muscle damage). Ready-to-use liquid stable reagent. Formulated to eliminate interference from pyruvates. Application sheets are ...
This Universal 24" X 18" (61 X 45.7cm.) shaker platforms will accept any Thermo Forma shaker flask clip....
Biology Products: